Fundraising Fox

Memo Therapeutics

Founded 2012 · 5 known investors

memo-therapeutics.com ↗

Memo Therapeutics AG is a late-stage biotech company developing therapeutic antibodies for patients with viral infections and cancer. Its lead program, potravitug, is in Phase II development to treat BK polyomavirus infection in kidney transplant recipients, with additional oncology programs targeting antibodies derived from tumor-infiltrating B-cells.

BiotechMedical Devices

Investors · 5

Adjuvant CapitalNew York · $10M – $25M
Fresenius Medical Care VenturesBad Homburg
Kurma PartnersParis · $162K – $10.8M
Ysios CapitalBarcelona · $5.4M – $21.6M
redalpinereportedZug · $108K – $2.2M

In the news

Ipsen completes acquisition of Memo Therapeutics By Investing.cominvesting.com · Jul 2026Memo Therapeutics AG Increase Series C Financing to CHF 45 Million - Memo Therapeuticsmemo-therapeutics.com · May 2024Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients - Memo Therapeuticsmemo-therapeutics.com · Nov 2023Memo Therapeutics raises CHF 14 million for immunotherapy of COVID-19 – Swiss Biotechswissbiotech.org · Nov 2020Memo Therapeutics acquired by Ipsen — 797.0M USD (Jul 2026) | Seedtableseedtable.com

Frequently asked questions

What does Memo Therapeutics do?
Memo Therapeutics AG is a late-stage biotech company developing therapeutic antibodies for patients with viral infections and cancer. Its lead program, potravitug, is in Phase II development to treat BK polyomavirus infection in kidney transplant recipients, with additional oncology programs targeting antibodies derived from tumor-infiltrating B-cells.
Who are Memo Therapeutics's investors?
Memo Therapeutics's investors include Adjuvant Capital, Fresenius Medical Care Ventures, Kurma Partners, Ysios Capital, redalpine.